-
Global Biotechnology & Pharmaceutical Markets3 weeks agoPacira partners with Molteni for Exparel commercialisation
Exparel (bupivacaine liposome injectable suspension), is a long-acting local analgesic used for postsurgical pain management. Under the agreement, Pacira will obtain an undisclosed upfront payment, alongside...
-
Global Biotechnology & Pharmaceutical Markets3 weeks agoMerck’s new BioReliance® Facility in Darmstadt: supporting biologics development and commercialization in Europe
Merck’s new BioReliance® Facility in Darmstadt, Germany, will support biologics testing, GMP release testing and stability studies in Europe. The post Merck’s new BioReliance® Facility in...
-
Global Biotechnology & Pharmaceutical Markets3 weeks agoChina deals, Beam lawsuit, MFN models, Nobel winners — a BioCentury podcast
BIOCENTURY | DEALSCHINA DEALS, BEAM LAWSUIT, MFN MODELS, NOBEL WINNERS — A BIOCENTURY PODCASTPharma partnering in China gets earlier and broader
-
Global Biotechnology & Pharmaceutical Markets3 weeks agoSTAT+: New Trump regulations would clean up health care pricing disclosures
The Trump administration is continuing its effort to bring more transparency to the cost of health care.
-
Global Biotechnology & Pharmaceutical Markets3 weeks agoPrecision for All: Closing the gap between innovation and impact
Why diagnostic-driven therapies need a new commercialization model to reach more eligible patients.
-
Global Biotechnology & Pharmaceutical Markets4 weeks agoPharma partnering in China gets earlier and broader
BIOCENTURY | DATA BYTEPHARMA PARTNERING IN CHINA GETS EARLIER AND BROADERMerck, Novo and Novartis pay ≥$300M apiece for early assets as China partnering expands beyond cancer...
-
Global Biotechnology & Pharmaceutical Markets4 weeks agoWatching Cancer Proteins in Real Time, with Help from Rare Earth Elements
A long-duration single-molecule imaging platform from the Broad Institute and MIT has revealed unexpected stability in homodimers of HER3, one of the most enigmatic members of...
-
Global Biotechnology & Pharmaceutical Markets4 weeks agoThis week in charts: Kodiak’s big comeback and Hengrui’s dealmaking
The latest installment in BioPharma Dive’s data visualization series features a closer look at Kodiak’s stock performance and Hengrui's ties with U.S. and European drugmakers.
-
Global Biotechnology & Pharmaceutical Markets4 weeks agoSTAT+: Lilly bypasses Australian pharmacies with DTC model
Eli Lilly is launching LillyDirect to deliver Mounjaro straight to Australian patients’ doors — and local doctors and pharmacists aren’t thrilled.
-
Global Biotechnology & Pharmaceutical Markets4 weeks ago
BIOSPAIN 2026: The challenge of turning strong science into scale
BIOSPAIN returned to Bilbao this week with much of the conversation focused not so much on whether Spain, and more broadly, Europe, can produce strong biotech...
Genmab’s cancer bispecific delivers early survival win in ‘exceedingly positive’ Phase 3 readout
Genmab’s cancer bispecific delivers early OS win in ‘exceedingly positive’ Phase 3 readout
STAT+: HHS moves to allow compounding of some unapproved peptides
Novartis buys Synnovation’s PI3Kα inhibitors for $3 billion
Novartis to pay $2B upfront to take next-gen PI3Kα inhibitor from Synnovation
